REDW — Redwood Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK25.16m
- SEK24.34m
Annual income statement for Redwood Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -17.1 | -9.5 | -9.38 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 15.5 | 14.5 | 20.5 | 13 | 13.5 |
| Operating Profit | -15.5 | -14.5 | -20.5 | -13 | -13.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -15.8 | -14.5 | -20.8 | -13 | -14.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.8 | -14.5 | -20.8 | -13 | -14.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.8 | -14.5 | -20.8 | -13 | -14.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.8 | -14.5 | -20.8 | -13 | -14.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -26.5 | -22.6 | -26.1 | -10.3 | -4.43 |
| Dividends per Share |